Emergence of PER-2 and VEB-1a in Acinetobacter baumannii Strains in the Americas
| Autor: | Miryam Vázquez, Melina Rapoport, Marcelo Galas, Viviana Cagnoni, Alejandra Corso, M Tokumoto, Alejandro Petroni, Adriana Procopio, Fernando Pasteran, Diego Faccone |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Acinetobacter baumannii
Imipenem medicine.drug_class Molecular Sequence Data Cephalosporin Ceftazidime Microbial Sensitivity Tests Polymerase Chain Reaction Meropenem beta-Lactamases Microbiology Drug Resistance Multiple Bacterial medicine Humans Pharmacology (medical) Letters to the Editor Pharmacology biology Accession number (library science) Escherichia coli Proteins biochemical phenomena metabolism and nutrition Acinetobacter biology.organism_classification Infectious Diseases Americas Acinetobacter Infections medicine.drug Piperacillin |
| Zdroj: | Antimicrobial Agents and Chemotherapy. 50:3222-3224 |
| ISSN: | 1098-6596 0066-4804 |
| Popis: | Antimicrobial treatment of Acinetobacter infections may be limited because of the emergence of extended-spectrum β-lactamase (ESBL)- and carbapenemase-producing multiresistant strains (7, 13). Non-TEM-, non-SHV-derived ESBLs (such as PER and VEB) have been documented in Acinetobacter isolates from Europe and Asia (7) but not yet from the Americas. Recently, an increasing trend has been documented in carbapenem and extended-spectrum cephalosporin resistance in Acinetobacter isolates in Buenos Aires. Indeed, data from the Whonet-Argentina Network showed that, in 2004, more than 80% of Acinetobacter isolates were resistant to extended-spectrum cephalosporins. In addition, imipenem resistance increased from 5% to 54%, in the period from 2000 to 2004 (M. Galas, unpublished results). National ESBL surveillance is performed by Whonet-Argentina Network participants using a modification of the CLSI antibiogram (8), consisting of a synergy test with ceftazidime or cefepime and amoxicillin-clavulanic acid (distance between disks, 20 mm, center to center). FAV-1 and M5179 were the first putative ESBL-producing Acinetobacter baumannii strains isolated at two hospitals in Buenos Aires in 2000 and 2003, respectively. FAV-1 was a colonizer from the urine of a patient hospitalized for lung transplantation. M5179 was from the peritoneal fluid of a patient with hemolytic-uremic syndrome. Strains were confirmed to be A. baumannii by using the API 20NE system (bioMerieux, Marcy l'Etoile, France) combined with their ability to grow at 44°C. MICs (micrograms per milliliter) for FAV-1 and M5179 determined by agar dilution (10) were, respectively, as follows: ticarcillin, 1,024 and 1,024; piperacillin, 512 and 256; piperacillin-tazobactam, 512 and 0.5; ampicillin-sulbactam, 8 and 8; cefotaxime, 64 and 64; cefotaxime-clavulanate, 64 and 8; ceftazidime, 64 and 512; ceftazidime-clavulanate, 16 and 2; cefepime, 64 and 64; cefepime-clavulanate, 16 and 4; aztreonam, 512 and 512; imipenem, 8 and 0.5; meropenem, 8 and 0.5; amikacin, 128 and 32; gentamicin, 2 and 32; trimethoprim-sulfamethoxazole, 128 and 8; ciprofloxacin, 32 and 0.12; rifampin, 2 and >32; minocycline, 0.5 and |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|